Nadolol plus isosorbide mononitrate compared with sclerotherapy for the prevention of variceal rebleeding

New England Journal of Medicine

Volumn 334, Issue 25, 1996, Pages 1624-1629

  Villanueva, Càndid ^a   Balanzó, Joaquim ^a   Novella, Maria T ^a   Soriano, German ^a   Sáinz, Sergio ^a   Torras, Xavier ^a   Cussó, Xavier ^a   Guarner, Carlos ^a   Vilardell, Francisco ^a  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ISOSORBIDE MONONITRATE; NADOLOL;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; ESOPHAGUS VARICES BLEEDING; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RECURRENT DISEASE; TREATMENT OUTCOME; VARICOSIS;

ACTUARIAL ANALYSIS; ADRENERGIC BETA-ANTAGONISTS; DRUG THERAPY, COMBINATION; ESOPHAGEAL AND GASTRIC VARICES; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMANS; ISOSORBIDE DINITRATE; MALE; MIDDLE AGED; NADOLOL; RECURRENCE; SCLEROTHERAPY; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 0030003919     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199606203342502     Document Type: Article

References (36)

1. Graham DY, Smith JL. The course of patients after variceal hemorrhage. Gastroenterology 1981;80:800-9.
2. Ready JB, Rector WG. Morbidity and mortality of portal hypertension. Drugs 1989;37:Suppl 2:13-24.
3. Infante-Rivard C, Esnaola S, Villeneuve JP. Role of endoscopic variceal sclerotherapy in the long-term management of variceal bleeding: a metaanalysis. Gastroenterology 1989;96:1087-92.
4. D'Amico G, Pagliaro L, Bosch J. The treatment of portal hypertension: a meta-analytic review. Hepatology 1995;22:332-54.
5. Fleig WE, Stange EF, Hunecke R, et al. Prevention of recurrent bleeding in cirrhotics with recent variceal hemorrhage: prospective, randomized comparison of propranolol and sclerotherapy. Hepatology 1987;7:355-61.
6. Westaby D, Poison RJ, Gimson AES, Hayes PC, Hayllar K, Williams R. A controlled trial of oral propranolol compared with injection sclerotherapy for the long-term management of variceal bleeding. Hepatology 1990;11:353-9.
7. Rossi V, Cales P, Burtin P, et al. Prevention of recurrent variceal bleeding in alcoholic cirrhotic patients: prospective controlled trial of propranolol and sclerotherapy. J Hepatol 1991;12:283-9.
8. Dollet JM, Champigneulle B, Patris A, Bigard MA, Gaucher P. Sclérothérapie endoscopique contre propranolol après hémorragie par rupture de varices oesophagiennes chez le cirrhotique: résultats à 4 ans d'une étude randomisée. Gaslroenterol Clin Biol 1988;12:234-9.
9. Alexandrino PT, Alves MM, Correia JP. Propranolol or endoscopic sclerotherapy in the prevention of recurrence of variceal bleeding: a prospective, randomized controlled trial. J Hepatol 1988;7:175-85.
10. Dasarathy S, Dwivedi M, Bhargava DK, Sundaram KR, Ramachandran K. A prospective randomized trial comparing repeated endoscopic sclerotherapy and propranolol in decompensated (Child class B and C) cirrhotic patients. Hepatology 1992;16:89-94.
11. Terés J, Bosch J, Bordas JM, et al. Propranolol versus sclerotherapy in preventing variceal rebleeding: a randomized controlled trial. Gastroenterology 1993;105:1508-14.
12. Schuman BM, Beckman JW, Tedesco FJ, Griffin JW Jr, Assad RT. Complications of endoscopic injection sclerotherapy: a review. Am J Gastroenterol 1987;82:823-30.
13. García-Pagán JC, Feu F, Bosch J, Rodés J. Propranolol compared with propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis: a randomized controlled study. Ann Intern Med 1991;114:869-73.
14. Garcia-Pagán JC, Navasa M, Bosch K, Bru C, Pizcueta P, Rodés J. Enhancement of portal pressure reduction by the association of isosorbide-5-mono-nitrate to propranolol administration in patients with cirrhosis. Hepatology 1990;11:230-8.
15. Gatta A, Sacerdoti D, Merkel C, Milani L, Battaglia G, Zuin R. Effects of nadolol treatment on renal and hepatic hemodynamics and function in cirrhotic patients with portal hypertension. Am Heart J 1984;108:1167-72.
16. Idéo G, Bellati G, Fesce E, Grimoldi D. Nadolol can prevent the first gastrointestinal bleeding in cirrhotics: a prospective, randomized study. Hepatology 1988;8:6-9.
17. Bosch J, García-Pagán JC, Feu F, et al. New approaches in the pharmacologic treatment of portal hypertension. J Hepatol 1993;17:Suppl 2:S41-S45.
18. de Franchis R, Pascal JP, Ancona E, et al. Definitions, methodology and therapeutic strategies in portal hypertension: a Consensus Development Workshop, Baveno, Lake Maggiore, Italy, April 5 and 6, 1990. J Hepatol 1992;15:256-61.
19. Balanzó J, Such J, Sáinz S, et al. Long term survival and severe rebleeding after variceal sclerotherapy. Surg Gynecol Obstet 1990;171:489-92.
20. Gardner MJ, Altman DG, eds. Statistics with confidence: confidence intervals and statistical guidelines. London: British Medical Journal, 1989.
21. Christensen E. Multivariate survival analysis using Cox's regression model. Hepatology 1987;7:1346-58.
22. Armitage P, Berry G. Statistical methods in medical research. 2nd ed. Oxford, England: Blackwell Scientific, 1987.
23. Balanzó J, Sáinz S, Espinós JC, et al. Efficacy of ethanolamine and polidocanol in the eradication of esophageal varices: a prospective randomized trial. Endoscopy 1989;21:251-3.
24. McCormick PA, Feu F, Sabrin C, Planas R. Propranolol and isosorbide mononitrate versus sclerotherapy or shunt surgery for the prevention of variceal rebleeding: a randomized trial. Hepatology 1994;20:Suppl:106A. abstract.
25. Burroughs AK, Mezzanotte G, Phillips A, McCormick PA, McIntyre N. Cirrhotics with variceal hemorrhage: the importance of the time interval between admission and the start of analysis for survival and rebleeding rates. Hepatology 1989;9:801-7.
26. Burroughs AK, McCormick PA. Prevention of variceal rebleeding. Gastroenterol Clin North Am 1992;21:119-47.
27. Polio J, Groszmann RJ. Hemodynamic factors involved in the development and rupture of esophageal varices: a pathophysiologic approach to treatment. Semin Liver Dis 1986;6:318-31.
28. Garcia-Tsao G, Groszmann RJ, Fisher RL, Conn HO, Atterbury CE, Glickman M. Portal pressure, presence of gastroesophageal varices and variceal bleeding. Hepatology 1985;5:419-24.
29. Groszmann RJ, Bosch J, Grace ND, et al. Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage. Gastroenterology 1990;99:1401-7.
30. Feu F, García-Pagán JC, Bosch J, et al. Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis. Lancet 1995;346:1056-9.
31. Salmerón JM, del Arbol LR, Ginés A, et al. Renal effects of acute isosorbide-5-mononitrate administration in cirrhosis. Hepatology 1993;17:800-6.
32. Vorobioff J, Picabea E, Gamen M, et al. Propranolol compared with propranolol plus isosorbide dinitrate in portal-hypertensive patients: long-term hemodynamic and renal effects. Hepatology 1993;18:477-84.
33. Henriksen JH, Ring-Larsen H. Renal effects of drugs used in the treatment of portal hypertension. Hepatology 1993;18:688-95.
34. Morillas RM, Planas R, Cabré E, et al. Propranolol plus isosorbide-5-mono-nitrate for portal hypertension in cirrhosis: long-term hemodynamic and renal effects. Hepatology 1994;20:1502-8.
35. Merkel C, Gatta A, Donada C, et al. Long-term effect of nadolol or nadolol plus isosorbide-5-mononitrate on renal function and ascites formation in patients with cirrhosis. Hepatology 1995;22:808-13.
36. D'Amico G, Montalbano L, Traina M, et al. Natural history of congestive gastropathy in cirrhosis. Gastroenterology 1990;99:1558-64.